PDI Appoints David E. Kerr Senior Vice President of Business Development

SADDLE RIVER, N.J.--(Business Wire)--
PDI, Inc. (NASDAQ: PDII), a pioneer in providing contract sales and
commercialization services to the biopharmaceutical industry, announces the
appointment of pharmaceutical executive David E. Kerr to the position of Senior
Vice President of Business Development, to provide leadership and strategy for
the commercial success of PDI`s contract sales business. Mr. Kerr will report to
Nancy Lurker, PDI`s Chief Executive Officer.

Most recently, Mr. Kerr was Senior Vice President of Commercial Business at Endo
Pharmaceuticals, where he was accountable for all facets of the company`s
commercial activities, including $1.3 billion in brand and generics sales,
marketing, portfolio planning, strategic marketing, contracting and pricing, and
launched three new products that added more than $200 million in new revenue for
the company. From 2001 to 2006 at Endo, David was Vice President of Business
Development, responsible for leading product licensing and acquisition
activities, contributing 14 large product transactions with mid-cap and large
pharmaceutical companies, with transaction value estimated at over $500 million.

"David brings a deep understanding of all aspects of the pharmaceutical
industry, a strong appreciation of its needs and challenges, and proven success
in evaluating and closing large and complex transactions. A seasoned
pharmaceutical executive, David`s business-to-business experience, honed through
extensive deal flow, will be an integral part of our future growth. This,
combined with his knowledge of launching products, managing life cycles and
building and realigning sales forces from the point of view of our clients and
potential clients, makes David the ideal person to lead our business development
activities and we are very excited that he has chosen to join PDI," said Nancy
Lurker, Chief Executive Officer of PDI.

Mr. Kerr said, "I am delighted to join a premier contract sales organization
like PDI at a time when pharmaceutical companies are looking for opportunities
to improve promotional return on investment, reduce expenses and increase
efficiency through the integration of their internal teams with outsourced teams
in their sales function. I look forward to working with Nancy and the rest of
the PDI team to reach our goal of expanding market share in contract sales."

Prior to Endo Pharmaceuticals, Mr. Kerr spent six years at Knoll Pharmaceutical
Company, Inc., the pharmaceutical division of BASF until its 2001 acquisition by
Abbott Laboratories. Hired in 1996 as a Manager of Strategic Sales Force
Planning and Operations, Mr. Kerr was quickly promoted to Director of Sales
Operations and Planning where he managed all aspects of the operation of a
700-member sales force, with a leadership role in the launch of a contract sales
force and sales force automation projects. By 2000, he was promoted to Senior
Director of the company`s Pain Management Business Unit, Knoll`s second largest
and fastest growing business unit in terms of sales and profits. He was
responsible for new business development with direct sales of $175 million and
$50 million in business development spending. He was responsible for the
direction of all marketing, market development, advocacy development,
professional services, and clinical development. During his tenure at Knoll, he
was accountable for the Vicodin® and Dilaudid® family of brands and received the
company`s President`s Award for the initiative to launch two co-promotions for
Vicoprofen®.

Mr. Kerr began his career with E.I. DuPont de Nemours & Company, where he spent
15 years working his way up from Account Representative through Field Sales
Management, to Market Manager of Integrated Health Networks Diagnostics
Division. In this position he had leadership responsibility for the development
and implementation of marketing and sales strategies for Integrated Health
Networks, with a focus on business-to-business relationships in the Western U.S.

Mr. Kerr received a Bachelor of Science degree from Pennsylvania State
University in State College, Penn. and an MBA from the University of Delaware in
Newark, Del. He is replacing David Stievater, who has been named Senior Vice
President of Product Development.

About PDI

PDI provides commercialization services for established and emerging
biopharmaceutical companies. The Company is dedicated to maximizing the return
on investment for its clients by providing strategic flexibility, sales,
marketing and commercialization expertise.

PDI currently operates in three business segments: Sales Services, Marketing
Services and Product Commercialization. Our sales services include Performance
Sales Teams, which are dedicated pharmaceutical sales force teams for specific
customers; Select Access, our targeted sales solution that leverages an existing
sales force and infrastructure; and PDI ON DEMAND, a suite of innovative sales
services that provide rapid, customized sales force solutions tailored to meet
the local, regional and seasonal needs of our customers. Our marketing services
include marketing research and consulting services through TVG, and medical
communications services through Pharmakon. Our product commercialization
solutions leverage our considerable sales and marketing expertise to manage
products throughout their lifecycles. PDI's experience extends across multiple
therapeutic categories and includes office- and hospital-based initiatives.

For more information, please visit the Company`s website at www.pdi-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events
and financial performance. These statements are based on current expectations
and assumptions involving judgments about, among other things, future economic,
competitive and market conditions and future business decisions, all of which
are difficult or impossible to predict accurately and many of which are beyond
PDI`s control. These statements also involve known and unknown risks,
uncertainties and other factors that may cause PDI`s actual results to be
materially different from those expressed or implied by any forward-looking
statement. Such factors include, but are not limited to: effects of the current
worldwide economic and financial crisis; changes in outsourcing trends or a
reduction in promotional, marketing and sales expenditures in the
pharmaceutical, biotechnology and life sciences industries; early termination of
a significant services contract or the loss of one or more significant clients
or a material reduction in service revenues from such clients; the ability to
obtain additional funds in order to implement PDI`s business model; the ability
to successfully develop and generate sufficient revenue from any product
commercialization opportunities; the ability to successfully identify, complete
and integrate any future acquisitions and the effects of any such acquisitions
on PDI`s ongoing business; the ability to meet performance goals in
incentive-based and revenue sharing arrangements with clients; competition in
PDI`s industry; the ability to attract and retain qualified sales
representatives and other key employees and management personnel; product
liability claims against PDI; changes in laws and healthcare regulations
applicable to PDI`s industry or PDI`s, or its clients`, failure to comply with
such laws and regulations; the ability to increase revenues and successfully
manage the size of PDI`s operations; volatility of PDI`s stock price and
fluctuations in its quarterly revenues and earnings; potential liabilities
associated with insurance claims; failure of, or significant interruption to,
the operation of its information technology and communications systems; the
results of any future impairment testing for goodwill and other intangible
assets; and the risk factors detailed from time to time in PDI's periodic
filings with the Securities and Exchange Commission, including without
limitation, PDI's Annual Report on Form 10-K for the year ended December 31,
2008, and PDI's subsequently filed quarterly reports on Form 10-Q and current
reports on Form 8-K. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these forward-looking
statements. In addition, these statements speak only as of the date of this
press release and, except as may be required by law, PDI undertakes no
obligation to revise or update publicly any forward-looking statements for any
reason.

PDI CONTACT:
Jeffrey E. Smith, Chief Financial Officer, 201-258-8451
jesmith@pdi-inc.com
www.pdi-inc.com
or
INVESTOR CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Copyright Business Wire 2009